Association of Human Leucocyte Antigen Polymorphism with Coronavirus Disease 19 in Renal Transplant Recipients

Narayan Prasad *, Brijesh Yadav, Swayam Prakash, Deependra Yadav, Ankita Singh, Sonam Gautam, Dharmendra Bhadauria, Anupama Kaul, Manas Ranjan Patel, Manas Ranjan Behera, Ravi Shankar Kushwaha and Monika Yachha

Department of Nephrology and Renal Transplantation, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India
* Correspondence: narayan.nephro@gmail.com

Abstract: Human leucocyte antigens (HLAs) are highly polymorphic glycoproteins expressed at the surface of all nucleated cells. It is required for the SARS-CoV-2 peptide antigen presentation to immune cells for their effector response. However, polymorphism in HLA significantly impacts the binding of SARS-CoV-2 antigenic peptide to the HLA pocket and regulates immune activation. In this study, 514 renal transplant recipients (RTRs) were recruited from the outpatient department and categorized either into symptomatic (n = 173) or asymptomatic groups (n = 341) based on Coronavirus disease-19 (COVID-19) symptoms. The anti-SARS-CoV-2 spike protein-specific IgG antibody titer was measured by chemiluminescent microparticle immune-assay methods in 310 RTRs. The HLA details of 514 patients were retrieved from the electronic medical records and analyzed retrospectively. We found that HLA antigen allele A*24 was significantly associated with asymptomatic infection in 22.78%, HLA C*02 in 4.51%, DRB1*12 in 10.85%, and HLA DQA1*02 in 27.74% of RTRs. Whereas HLA A*29 in 3.46%, A*33 in 26.01%, B*13 in 10.40%, DRB1*10 in 4.62%, DRB1*15 in 39.30%, DRB1*30 in 1.15%, and DQA1*60 in 3.57% of RTRs were associated with symptomatic infection. HLA DRB1*13 and DRB1*15 were associated with moderate to severe degrees of COVID-19 disease. The seroconversion rate in asymptomatic patients was 118/137 (86.13%), had a median titer of 647.80 au/mL, compared to symptomatic patients 148/173 (85.54%) with a median titer of 400.00 au/mL, which was not significant between the two groups (p = 0.88 and 0.13).

In conclusion, HLA alleles A*24, C*02, DRB1*12, and DQA1*02 were significantly associated with asymptomatic infection, and A*29, A*33, B*13, DRB1*10, DRB1*15, and DQA1*60 were significantly associated with symptomatic infection. HLA DRB1*13 and DRB1*15 were associated with moderate to severe degrees of COVID-19 disease.

Keywords: human leucocyte antigen; anti-SARS-CoV-2 antibody; seroconversion; alleles

1. Introduction

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection emerged as a pandemic in December 2019 from Wuhan, China. Until 12 August 2022, 585 million people tested positive for SARS-CoV-2, and 6.4 million people succumbed to death [1]. Several co-morbid factors, such as age, obesity, diabetes, hypertension, and human leucocyte antigen (HLA) polymorphism, have been reported to be associated with infection and patient outcomes [2]. However, people from different ethnicities responded differently to the SARS-CoV-2 pandemic [3]. Many people develop mild to severe COVID-19 symptoms while others remain asymptomatic, suggesting various degrees of immune activation against the SARS-CoV-2 virus. The immune system of RTRs remains compromised due to the maintenance of immunosuppression. They are vulnerable to higher SARS-CoV-2 infection, mortality, and poor seroconversion rate than the general population [4,5].
For immune cell activation, a presentation of virus antigen through the HLA to T and B cells is required. There are more than 27,000 alleles in HLA, making an individual distinct from others. HLAs are encoded by the gene located at the short arm of chromosome 6p21.3. A polymorphism in HLA is associated with different cellular and humoral immune responses against antigens and vaccines [6]. HLA class 1 comprises A, B, and C, whereas 2 comprises DP, DQ, and DR. The polymorphism of these two classes of HLA is associated with different susceptibility to developing autoimmune diseases and infection clearance [7–9].

HLAs are unique glycoproteins expressed over the cell surface of all nucleated cells. HLAs are adopted for presenting pathogenic antigens to immune cells to trigger the immune response. Antigens from the microbial components and self-altered cells are endocytosed by the antigen-presenting cell (APCs), such as macrophages, Dendritic, B cells, and other nucleated cells. After intracellular processing, antigen peptides are presented through HLA to cognate T and B cell receptors for triggering appropriate cellular responses [10]. A huge polymorphism occurs in the nucleotide sequence of the gene encoding for HLA peptides [11]. The antigen peptide epitope binds to the HLA pocket peptide through a non-covalent bond; thus, the nature of the amino acid in the HLA binding pocket may affect the binding affinity with antigen epitopes, resulting in the activation of different degrees of the cellular and humoral immune response [10].

HLA polymorphisms are linked with the different susceptibility of microbial infections such as influenza-A (H1N1) [12], hepatitis B virus (HBV) [13], hepatitis C virus (HCV) [14], dengue [15], HIV [16], and tuberculosis [9]. Different populations and races responded to the SARS-CoV-2 virus differentially [3]. Even in India, people from other states reacted to the virus differently [17]. It suggests an association of HLA polymorphism in differential susceptibility for acquiring SARS-CoV-2 infection and immune response. However, there is a paucity of data on the association of HLA polymorphism with the severity of COVID-19 disease on immunocompromised renal transplant recipients (RTRs). Therefore, in the current study, we have retrospectively analyzed the HLA alleles polymorphism association with symptomatic and asymptomatic SARS-CoV-2 infection and COVID-19 severity in RTRs.

2. Material and Methods

2.1. Patient Recruitment

A total of 514 live-related renal transplant recipients were recruited from the outpatient department, visiting for routine follow-ups. All symptomatic patients had reverse transcriptase polymerase chain reaction (RT-PCR) positive SARS-CoV-2 infection. Patients and family members were interviewed about the SARS-CoV-2 symptoms. Based on self-reported symptoms of COVID-19 disease, such as myalgia, fever, dry cough, loss of taste and smell, and tiredness, patients were categorized as either asymptomatic (n = 314) with no COVID-19 symptoms or symptomatic (n = 173), having any of the above symptoms. Based on the criteria laid down by the Revised Guidelines on Clinical Management of COVID-19, Ministry of Health and Family Welfare, the Government of India [18], COVID-19 was classified as mild when symptoms were present without features of viral pneumonia on imaging (X-ray chest or high-resolution computed tomography (HRCT) scans), moderate if manifestation were present, while severe disease refers to the presence of hypoxia with respiratory rate >30 breaths/min, severe respiratory distress, or SpO2 < 90% on room air, including acute respiratory distress syndrome (ARDS).

2.2. Blood Sample Collection and Anti-Spike Protein Analysis

Anti-Spike protein IgG titer was analyzed as described in our previous study [19]. A 5-mL blood sample was collected in EDTA vials from the 310 patients after collecting written consent from each patient. The blood sample was centrifuged at 1500 rpm for plasma separation. Plasma was stored at −20 °C till the immunoglobulin-G (IgG) titer measurement. In brief, plasma was incubated with anti-SARS-CoV-2 antigen-coated paramagnetic
beads and washed to remove nonspecific bindings. Following washing, an acridinium labeled anti-human IgG conjugate was added and incubated. The nonspecific binding of IgG was removed by washing, and a pre-trigger and trigger solution of hydrogen peroxide and sodium hydroxide was added; this resulted in a chemiluminescent mixture formation. The intensity of the chemiluminescent mixture was measured on the Architect platform (Abbott diagnostic, Longford, Ireland) in a relative light unit (RLU). Further samples of RLU were normalized with calibrators as per the World Health Organization’s guidelines [20,21].

2.3. Human Leucocyte Antigen Analysis

We have retrospectively analyzed the HLA alleles profile of 514 live-related renal transplant recipients from their electronic medical records for HLA-A, B DR, and in 239 RTRs for HLA-C and DQA1. These antigen alleles were determined previously at the time of transplantation by the polymerase chain reaction-single strand oligonucleotide (PCR-SSO) methods using LIFE CODES HLA Typing Kits (Immucor, Diagnostic, Springfield, IL, USA) on Luminex Xponent platform (version 3.1). All samples were typed at the alleles group level only.

2.4. Statistical Analysis

Continuous variables were expressed as mean ± standard deviation. Student’s t-test was used to compare the variables between the groups. Categorical variables were expressed in percentages. The antibody titer was expressed as the median and interquartile range (IQR). Fisher’s exact test or Chi-square test was used to compare the categorical values between the groups. A p-value < 0.05 was considered to be significant. Logistic regression was performed to determine the other predictors for symptomatic and asymptomatic infection. Statistical analysis was performed with the SPSS software version 20 (IBM, corporation, Armonk, NY, USA).

3. Result

3.1. Demographic and Clinical Characteristics of Patients

The demographic and clinical characteristics of the patients are shown in Table 1. There was a significant difference in the patient’s age, BMI, TLCs, eGFR, and induction regimen used between symptomatic and asymptomatic RTR.

3.2. HLA Class 1 Alleles and Association with COVID-19 Symptoms

We have found that HLA antigen alleles A*24 were significantly associated with asymptomatic infection in 22.78% of RTRs, whereas A*29 in 3.46% and A*33 in 26.01% of patients were significantly associated with symptomatic infection. Other HLA-A alleles, such as A*11 in 22.87% and A*68 in 10.55% of patients, were associated with asymptomatic infection. However, there was no significant difference between the symptomatic and asymptomatic COVID-19 RTRs.

Similarly, HLA B*13 alleles were significantly associated with symptomatic infection in 10.40% of RTRs. Similarly, other major alleles, such as HLA B*07 were associated with asymptomatic infection in 11.73% and B*35 in 20.52% of RTRs, and HLA B*40 was associated with symptomatic infection in 13.87% of RTRs. However, the difference was non-significant between the symptomatic and asymptomatic groups (Table 2). HLA C*02 allele was significantly associated with asymptomatic infection in 4.51% of RTRs. HLA C*03 in 22.61%, C*04 in 19.04%, C*07 in 26.19%, and C*12 in 8.33% of RTRs were associated with symptomatic infection, and HLA C*06 was associated with asymptomatic infection in 18.70% of RTRs. However, there was no significant difference between symptomatic and asymptomatic infection (Table 2).
Table 1. Demographic and clinical profile of RTRs with asymptomatic and symptomatic infection.

| Characteristics                        | Asymptomatic \((n = 341)\) | Symptomatic \((n = 173)\) | \(p\)-Value |
|----------------------------------------|-----------------------------|---------------------------|-------------|
| **Patients Age (Years)**               | 42.53 ± 11.35               | 39.76 ± 11.64             | 0.01        |
| **Gender**                             |                             |                           |             |
| M (%)                                  | 300 (87.97)                 | 148 (85.54)               | 0.48        |
| F (%)                                  | 41 (12.02)                  | 25 (14.45)                |             |
| **Post-transplant interval (months)**  | 84.92 ± 65.58               | 86.41 ± 65.14             | 0.80        |
| **BMI (kg/m\(^2\))**                  | 23.20 ± 5.22                | 24.56 ± 5.19              | 0.01        |
| **Hemoglobin (mg/dL)**                 | 12.74 ± 1.81                | 12.74 ± 1.94              | 0.99        |
| **TLC \((\times 10^3)/\mu L\)**       | 7.14 ± 2.44                 | 7.79 ± 2.59               | 0.005       |
| **Baseline serum creatinine (mg/dL)**  | 0.89 ± 0.37                 | 0.83 ± 0.34               | 0.10        |
| **Serum creatinine (mg/dL)**           | 1.57 ± 0.78                 | 1.62 ± 0.48               | 0.44        |
| **BUN (mg/dL)**                        | 23.20 ± 9.58                | 24.29 ± 12.66             | 0.27        |
| **Tacrolimus level (µg/L)**            | 5.55 ± 2.03                 | 5.91 ± 2.73               | 0.09        |
| **eGFR (mL/min/1.73 m\(^2\))**        | 64.96 ± 31.75               | 58.98 ± 21.37             | 0.026       |
| **Induction**                          |                             |                           |             |
| Basiliximab                            | 78                           | 57                        | 0.046       |
| ATG                                    | 85                           | 35                        |             |
| No Induction                           | 178                          | 81                        |             |
| **Patient blood group**                |                             |                           |             |
| A*+ve                                  | 79                           | 44                        | 0.76        |
| B*+ve                                  | 142                          | 64                        |             |
| AB*+ve                                 | 34                           | 17                        |             |
| O*+ve                                  | 86                           | 48                        |             |
| **Immunosuppression**                  |                             |                           |             |
| Tacrolimus                             | 320                          | 169                       | 0.055       |
| Cyclosporin                            | 21                           | 4                         |             |

BMI—Body mass index, TLCs—Total leucocyte count, BUN—Blood urea nitrogen, eGFR—Estimated glomerular filtration rate, ATG—Anti-thymocyte-globulin.

Table 2. HLA-A alleles frequency in RTRs with asymptomatic and symptomatic infection.

| HLA Alleles | Asymptomatic \(n = 341\) (%) | Symptomatic \(n = 173\) (%) | \(p\)-Value |
|-------------|--------------------------------|-----------------------------|-------------|
| A\(^*\)01   | 7 (2.052)                      | 3 (1.73)                    | 0.8         |
| A\(^*\)02   | 12 (3.51)                      | 10 (5.78)                   | 0.22        |
| A\(^*\)03   | 22 (6.45)                      | 10 (5.78)                   | 0.76        |
| A\(^*\)09   | 1 (0.29)                       | 0 (0)                       | 0.47        |
| A\(^*\)11   | 78 (22.87)                     | 23 (13.29)                  | 0.09        |
| A\(^*\)13   | 1 (0.29)                       | 0 (0)                       | 0.47        |
| A\(^*\)20   | 1 (0.29)                       | 0 (0)                       | 0.47        |
| A\(^*\)23   | 1 (0.29)                       | 0 (0)                       | 0.47        |
| A\(^*\)24   | 78 (22.87)                     | 26 (15.02)                  | 0.03        |
| A\(^*\)25   | 10 (2.93)                      | 2 (1.15)                    | 0.2         |
| A\(^*\)26   | 17 (4.98)                      | 10 (5.78)                   | 0.7         |
| A\(^*\)28   | 1 (0.29)                       | 0 (0)                       | 0.47        |
| A\(^*\)29   | 2 (0.58)                       | 6 (3.46)                    | 0.01        |
| A\(^*\)30   | 2 (0.58)                       | 3 (1.73)                    | 0.2         |
Table 2. Cont.

| HLA Alleles | Asymptomatic n = 341 (%) | Symptomatic n = 173 (%) | p-Value |
|-------------|--------------------------|-------------------------|---------|
| A*31        | 4 (1.173)                | 5 (2.89)                | 0.16    |
| A*32        | 7 (2.05)                 | 6 (3.46)                | 0.33    |
| A*33        | 57 (16.71)               | 45 (26.01)              | 0.01    |
| A*34        | 1 (0.29)                 | 0 (0)                   | 0.47    |
| A*36        | 0 (0)                    | 1 (0.57)                | 0.16    |
| A*38        | 0 (0)                    | 1 (0.57)                | 0.16    |
| A*66        | 2 (0.58)                 | 0 (0)                   | 0.31    |
| A*68        | 36 (10.55)               | 21 (12.13)              | 0.59    |
| A*74        | 1 (0.29)                 | 0 (0)                   | 0.47    |
| A*80        | 0 (0)                    | 1 (0.57)                | 0.16    |
| B*04        | 9 (2.63)                 | 7 (4.04)                | 0.38    |
| B*05        | 3 (0.87)                 | 0 (0)                   | 0.21    |
| B*07        | 40 (11.73)               | 8 (4.62)                | 0.09    |
| B*08        | 8 (2.34)                 | 5 (2.89)                | 0.7     |
| B*12        | 1 (0.29)                 | 0 (0)                   | 0.47    |
| B*13        | 10 (2.93)                | 18 (10.40)              | <0.0001 |
| B*14        | 3 (0.87)                 | 0 (0)                   | 0.21    |
| B*15        | 42 (12.31)               | 23 (13.29)              | 0.75    |
| B*18        | 9 (2.63)                 | 6 (3.46)                | 0.59    |
| B*27        | 16 (4.69)                | 6 (3.46)                | 0.51    |
| B*33        | 1 (0.29)                 | 0 (0)                   | 0.47    |
| B*35        | 70 (20.52)               | 32 (18.49)              | 0.58    |
| B*37        | 13 (3.81)                | 8 (4.62)                | 0.66    |
| B*38        | 4 (1.17)                 | 3 (1.73)                | 0.6     |
| B*39        | 7 (2.052)                | 1 (0.57)                | 0.2     |
| B*40        | 33 (9.67)                | 24 (13.87)              | 0.15    |
| B*41        | 2 (0.58)                 | 1 (0.57)                | 0.98    |
| B*44        | 25 (7.33)                | 13 (7.51)               | 0.94    |
| B*48        | 1 (0.29)                 | 0 (0)                   | 0.47    |
| B*50        | 5 (1.46)                 | 1 (0.57)                | 0.37    |
| B*51        | 6 (1.75)                 | 3 (1.73)                | 0.98    |
| B*52        | 15 (4.39)                | 3 (1.73)                | 0.12    |
| B*53        | 2 (0.58)                 | 0 (0)                   | 0.31    |
| B*55        | 3 (0.87)                 | 2 (1.15)                | 0.75    |
| B*56        | 2 (0.58)                 | 0 (0)                   | 0.31    |
| B*57        | 2 (0.58)                 | 1 (0.57)                | 0.98    |
| B*58        | 3 (0.87)                 | 0 (0)                   | 0.21    |
| B*70        | 5 (1.46)                 | 7 (4.04)                | 0.06    |
| B*80        | 1 (0.29)                 | 1 (0.57)                | 0.62    |
Table 2. Cont.

| HLA-Alleles | Asymptomatic $n = 155$ (%) | Symptomatic $n = 84$ (%) | $p$-Value |
|-------------|---------------------------|--------------------------|-----------|
| C*01        | 5 (3.22)                  | 1 (1.19)                 | 0.33      |
| C*02        | 7 (4.51)                  | 0 (0)                    | 0.04      |
| C*03        | 22 (14.19)                | 19 (22.61)               | 0.09      |
| C*04        | 24 (15.48)                | 16 (19.04)               | 0.48      |
| C*05        | 4 (2.58)                  | 5 (5.95)                 | 0.19      |
| C*06        | 29 (18.70)                | 10 (11.90)               | 0.17      |
| C*07        | 39 (25.16)                | 22 (26.19)               | 0.86      |
| C*08        | 3 (1.93)                  | 2 (2.38)                 | 0.81      |
| C*12        | 12 (7.74)                 | 7 (8.33)                 | 0.87      |
| C*14        | 3 (1.93)                  | 0 (0)                    | 0.2       |
| C*15        | 4 (2.58)                  | 2 (2.38)                 | 0.92      |
| C*17        | 1 (0.64)                  | 0 (0)                    | 0.46      |
| C*20        | 1 (0.64)                  | 0 (0)                    | 0.46      |
| C*70        | 1 (0.64)                  | 0 (0)                    | 0.46      |

* indicates separation.

3.3. HLA Class 2 Alleles and Association with COVID-19 Symptoms

We have analyzed the HLA class 2 antigen alleles' association with COVID-19 disease severity. HLA DRB1*10 in 4.62%, DRB*15 in 39.30%, and DRB1*30 in 1.15% of RTRs were significantly associated with symptomatic SARS-CoV-2 infection. DRB1*12 was associated with asymptomatic infection in 10.85% of RTRs. Similarly, DRB1*11 in 9.67% and DRB1*14 in 10.26% of patients were associated with asymptomatic infection (Table 3).

Table 3. HLA-DRB1 alleles frequency in RTRs with asymptomatic and symptomatic infection.

| HLA Alleles | Asymptomatic $n = 341$ (%) | Symptomatic $n = 173$ (%) | $p$-Value |
|-------------|---------------------------|--------------------------|-----------|
| DRB1*01     | 8 (2.34)                  | 4 (2.31)                 | 0.98      |
| DRB1*03     | 4 (1.17)                  | 0 (0)                    | 0.15      |
| DRB1*04     | 11 (3.22)                 | 9 (5.20)                 | 0.27      |
| DRB1*07     | 24 (7.03)                 | 14 (8.09)                | 0.66      |
| DRB1*08     | 9 (2.63)                  | 1 (0.57)                 | 0.10      |
| DRB1*10     | 3 (0.87)                  | 8 (4.62)                 | 0.005     |
| DRB1*11     | 33 (9.67)                 | 15 (8.67)                | 0.72      |
| DRB1*12     | 37 (10.85)                | 7 (4.04)                 | 0.014     |
| DRB1*13     | 43 (12.60)                | 24 (13.87)               | 0.78      |
| DRB1*14     | 35 (10.26)                | 14 (8.09)                | 0.43      |
| DRB1*15     | 120 (35.19)               | 68 (39.30)               | <0.001    |
| DRB1*16     | 7 (2.05)                  | 3 (1.73)                 | 0.80      |
| DRB1*30     | 0 (0)                     | 2 (1.15)                 | 0.047     |
| DRB1*40     | 1 (0.29)                  | 2 (1.15)                 | 0.22      |
| DRB1*70     | 4 (1.17)                  | 2 (1.15)                 | 0.98      |
| DRB1*80     | 2 (0.58)                  | 0 (0)                    | 0.31      |
Further, HLA DQA1*02 was significantly associated with asymptomatic infection in 27.74% of RTRs, whereas DQA1*60 was associated with symptomatic infection in 3.57% of RTRs (Table 3).

3.4. Anti-Spike Protein IgG Antibody Titer

We have compared the seroconversion rate and antibody titer in 310 RTRs with asymptomatic \((n = 137)\) and symptomatic \((n = 173)\) infections. The seroconversion rate in asymptomatic RTRs was 118/137 (86.13%) with a median titer of 647.80 au/mL compared to symptomatic RTRs 148/173 (85.54%), with a median titer of 400.00 au/mL, which was similar between the two groups \((p = 0.88 \text{ and } 0.13)\); as shown Table 4. Furthermore, RTRs with symptomatic infection have been home-quarantined in 137/173 (79.2%) and hospitalized in 36/173 (20.80%) patients. Patients with hospitalization had a higher seroconversion rate of 35/36 (97.2%) as compared to home quarantine 113/137 (82.48%) \((p = 0.03)\) (Table 4).

### Table 4. Seroconversion rate in symptomatic (home quarantined or hospitalized) and asymptomatic RTRs.

| Seroconversion | Asymptomatic \((n = 137)\) | Symptomatic \((n = 173)\) | \(p\)-Value |
|----------------|-----------------------------|-----------------------------|-------------|
| Yes (%)        | 118 (86.13%)                | 148 (85.54%)                | 0.88        |
| No (%)         | 19 (13.86%)                 | 25 (14.45%)                 |             |
| Median Antibody titer (au/mL) (IQR) | 647.80 (167.75–2524.25)     | 400.00 (154.10–1670.10)     | 0.13        |

### Symptomatic Infection \((n = 173)\)

| Seroconversion | HQ \((n = 137, 79.2\%\) | HSP \((n = 36, 20.8\%\) | \(p\)-Value |
|----------------|-------------------------|--------------------------|-------------|
| Yes            | 113 (82.48%)            | 35 (97.22%)              | 0.030       |
| No             | 24 (17.51%)             | 1 (2.77%)                |             |

HQ—Home quarantined, HSP—Hospitalized, IQR—Interquartile range.

3.5. Association of HLA with the Severity of COVID-19

Further, we analyzed the severity of HLA class I and II alleles with COVID-19 symptoms severity in hospitalized RTRs \((n = 36)\). We found only DRB1 alleles were significantly associated with COVID-19 symptoms severity. DRB1*13 alleles were associated with moderate severity of COVID-19 in 57.14% of patients. DRB1*15 was associated with a mild to moderate degree of COVID-19 severity in 42.5% and a severe degree in 33.3% of RTRs. While DRB1*16 and DRB1*40 were associated with severe COVID-19 in 33.3% of RTRs (Table 5).
Table 5. HLA association with severity of COVID-19 disease.

| HLA       | Mild (n = 26) | Moderate (n = 7) | Severe (n = 3) | p-Value |
|------------|---------------|-----------------|----------------|---------|
| DRB1*07 (%)| 1 (3.84)      | 0 (0)           | 0 (0)          |         |
| DRB1*11 (%)| 5 (19.23)     | 0 (0)           | 0 (0)          |         |
| DRB1*13 (%)| 4 (15.38)     | 4 (57.14)       | 0 (0)          |         |
| DRB1*14 (%)| 4 (15.38)     | 0 (0)           | 0 (0)          |         |
| DRB1*15 (%)| 11 (42.30)    | 3 (42.85)       | 1 (33.3)       | 0.005   |
| DRB1*16 (%)| 0 (0)         | 0 (0)           | 1 (33.3)       |         |
| DRB1*30 (%)| 1 (3.84)      | 0 (0)           | 0 (0)          |         |
| DRB1*40 (%)| 0 (0)         | 0 (0)           | 1 (33.3)       |         |

* indicates separation.

3.6. Other Predictors of Asymptomatic and Symptomatic Infection

Patient’s age (OR = 0.98, 95% CI 0.95–0.99, p = 0.01), hemoglobin (OR = 0.96, 95% CI 0.85–1.09, p = 0.45), and eGFR (OR = 0.98, 95% CI 0.98–1.00, p = 0.02) were associated with asymptomatic infection, whereas total leucocyte count (OR = 1.14, 95% CI 1.04–1.25, p < 0.001) and BMI (OR = 1.03, 95% CI 0.98–1.08; p = 0.36) were associated with the symptomatic infection.

4. Discussion

In this study, we have found that human leucocyte antigen alleles A*24 in 22.87%, HLA C*02 in 4.52%, and HLA DQA1*02 in 27.74% of RTRs were significantly associated with asymptomatic infection, whereas HLA alleles HLA B*13 in 4.62%, DRB1*10 in 4.62%, DRB1*15 in 39.30%, DRB1*30 in 1.15%, and DQA1*60 in 3.57% of patients were associated with symptomatic infection. The seroconversion rate and median titer of the antibody were similar between groups. HLA DRB1*13 and DRB1*15 were associated with a moderate to severe degree of COVID-19.

Antibody formation is required to protect from the SARS-CoV-2 infection, which requires a cellular immune response to be reckoned after infection or vaccination. The SARS-CoV-2 virus binds to the angiotensin-converting enzyme receptor. It enters the cell for its multiplication [22], which is sensed by the intracellular recognition system and flagged through HLA on its surface as an alarming signal. After intracellular processing of the SARS-CoV-2 peptide, antigen-presenting cells present to T and B cells for helper, effector, and humoral responses.

The antigen binding affinity to the HLA binding pocket primarily determines the potency of immune cell activation [23,24]. The HLA pocket is composed of the sequence of amino acids, which is encoded by the HLA genes. Due to microbial antigen overload, HLA genes undergo continuous shuffling of the nucleotide sequence resulting in huge polymorphism in HLA loci [25,26]. This results in a change in the nature of amino acids in the binding pocket, resulting in the overall strength of immune cell activation [11,23,27]. Both in vivo and in silico simulation shows that HLA-B*46:01 and HLA-B*54:01 in the Taiwanese population were associated with severe COVID-19, and HLA-B*1301 shows a protective association. In contrast, on subgroup analysis, we observed that HLA-B*13 was associated with a mild to moderate degree of symptomatic disease and 100% seroconversion rate with median anti-Spike IgG titer 1123.00 au/mL, which suggests robust seroconversion and efficient clearance of the virus. However, an in-silico study shows a weak antigen-presenting capacity of HLA-B*46:01 [24].

Further, one Italian study has shown an association of HLA-DRB1*15:01, DQB1*06:02, and B*27:07* with COVID-19 severity [28]. However, we observed only HLA-DRB1*15 association with symptomatic infection in 39.30% of RTRs, an in silico study has shown that HLA-DRB1*15 alleles can bind with different variants of SARS-CoV-2 peptides with multiple binding sites and present it to T and B cells with the highest capacity and gen-
erate a potent immune response, which is associated with a humoral immune response as seroconversion. This suggests exaggerated immune activation may be the cause of COVID-19 severity. However, this helps in the early clearance of the virus. We observed that HLA-DRB1*15 was significantly associated with symptomatic infection, and HLA-DRB1*13 and 15 were associated with mild to severe degrees of COVID-19 disease, which suggests both alleles may link with a robust immune response and seroconversion. In symptomatic groups, seroconversion was observed in 85.54% of patients. Since RTRs remain on continuous maintenance of triple immunosuppressive regimens, such as Tacrolimus, Mycophenolate mofetil, and Prednisolone, Mycophenolate is reported to hamper seroconversion against SARS-CoV-2 peptide significantly [27]. Thus, in these RTRs, overactivation did not happen, 79.2% of patients needed home quarantine, and 20.80% were hospitalized in the symptomatic group with mild to moderate COVID-19 in the majority. In the Mexican population, HLA-DRB1*01 was negatively associated with COVID-19-associated fatality [29]. However, in our current study, we did not observe any significant association of DRB1*01 with COVID-19 severity.

Further, in a normal Saudi Arabia population, HLA-A*01, B*56, DRB1*04, and DRB1*08 were significantly associated with COVID-19 infection, and HLA-A*03 and C*06 were associated with mortality. However, we did not observe any significant association with COVID-19 for these alleles. However, the frequency of HLA DRB1*04 was increased in asymptomatic patients, and C*06 and DRB1*08 were higher in asymptomatic patients [30].

Due to immunosuppression in RTR, seroconversion is less likely to happen, as evidence emerged from the western RTRs [31,32]. In this study, we have observed that 60% of RTRs did not experience any symptoms of COVID-19 and had a seroconversion rate of 86.13%, with a median titer of 647.80 au/mL compared to 85.54% seroconversion and median titer of 400.0 au/mL in the symptomatic group, which is consistent with our previous study on the seroconversion rate after whole virus-based vaccination in RTRs [33,34]. The observations further suggest that immunosuppression does not significantly hamper the seroconversion rate and may help in the reduction of COVID-19 severity. A few other studies have also shown that immunosuppressive steroids have significantly reduced inflammation-associated mortality in COVID-19 [35,36]. However, it delays viral clearance. Although, it is critical to decide the ideal window period after which the immunosuppressives should be started to prevent an exaggerated immune response. Our previous study showed that the whole virus antigens are more efficient in triggering seroconversion and clearance of the virus in RTRs [33]. The present study’s findings suggest that asymptomatic COVID-19 may be due to effective and rapid clearance of the virus. COVID-19 severity may be due to either over/under activation of an immune response. Patients with severe COVID-19 often show the features of activated helper Th17 and CD8+ cytotoxic-T cells, inflammatory cytokines, and lymphopenia [37,38]. The activation of T-helper and Cytotoxic T-cells may have a detrimental effect on the allograft in itself [39-41]. We did not observe any significant deterioration in allograft function in this study.

The limitation of our study is that HLA genotyping for HLA-C and DQA1 was available for only 239 patients, and the anti-SARS-CoV-2 spike protein antibody titer was measured in only 310 RTRs. The majority of RTRs included in the study were male (87.15%), as this was the proportion of patients going for transplantation in India. The small sample size remains the major limitation. Further, to establish the HLA association with COVID-19 disease severity, a larger study would be required.

5. Conclusions

HLA alleles A*24, C*02, DRB1*12, and DQA1*02 were significantly associated with asymptomatic COVID-19 and A*29, A*33, B*13, DRB1*10, DRB*15, and DRB1*30 were significantly associated with symptomatic COVID-19. HLA DRB1*13 and DRB1*15 were associated with moderate to severe degrees of COVID-19. The seroconversion rate was 85.54% in symptomatic and 86.13% in asymptomatic COVID-19 patients. The median antibody titer in symptomatic was 400 au/mL and in asymptomatic patients was 647.80 au/mL.
Author Contributions: Conceptualization, N.P. and B.Y.; Data curation, D.Y., A.S. and S.G.; Formal analysis, N.P. and B.Y.; Investigation, N.P. and D.Y.; Methodology, N.P., B.Y., A.S., S.G., M.R.P., R.S.K. and M.Y.; Project administration, N.P., B.Y., D.B. and M.R.P.; Resources, D.B., A.K., M.R.B., R.S.K. and M.Y.; Writing—original draft, B.Y.; Writing—review & editing, N.P., S.P., D.B., A.K., M.R.P., M.R.B. and R.S.K. All authors have read and agreed to the published version of the manuscript.

Funding: This project was not funded by any funding agencies. B.Y is supported by the Young Scientist grant of the Department of Health Research, New Delhi (Grant code- YSS/2020/000202/PRCYSS).

Institutional Review Board Statement: This study is approved by the institutional Ethics Committee. IEC code: 2022-102-IMP-EXP-48.

Informed Consent Statement: All the patient were informed about the study, and a written consent form was obtained from each patient before blood sampling.

Data Availability Statement: The data supporting this study’s findings are available from the corresponding author upon reasonable request.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/ (accessed on 12 August 2022).

2. Ruan, Q.; Yang, K.; Wang, W.; Jiang, L.; Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020, 46, 846–848. [CrossRef] [PubMed]

3. Rostami, A.; Sepidarkish, M.; Leeflang, M.M.G.; Riahi, S.M.; Nourollahpour Shiadeh, M.; Esfandyari, S.; Mokdad, A.H.; Hotez, P.J.; Zavala-Ruiz, Z.; Strug, I.; Anderson, M.W.; Gorski, J.; Stern, L.J. A polymorphic pocket at the P10 position contributes to peptide binding specificity in class II MHC proteins. Front. Immunol. 2021, 12, 331–340. [CrossRef] [PubMed]

4. Grupper, A.; Rabinowich, L.; Schwartz, D.; Schwartz, I.F.; Ben-Yehoyada, M.; Shashar, M.; Katchman, E.; Halperin, T.; Turner, D.; Goykman, Y.; et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am. J. Transpl. 2021, 21, 2719–2726. [CrossRef] [PubMed]

5. Ng, J.H.; Hirsch, J.S.; Wanchoo, R.; Sachdeva, M.; Sakhya, V.; Hong, S.; Jhaeveri, K.D.; Fishbane, S. Outcomes of patients with end-stage kidney disease hospitalized with COVID-19. Kidney Int. 2020, 98, 1530–1539. [CrossRef] [PubMed]

6. Ovsyannikova, I.G.; Dhiman, N.; Jacobson, R.M.; Poland, G.A. Human leukocyte antigen polymorphisms: Variable humoral immune responses to viral vaccines. Expert Rev. Vaccines 2006, 5, 33–43. [CrossRef]

7. Migliorini, F.; Torsiello, E.; Spiezia, F.; Oliva, F.; Tingart, M.; Maffulli, N. Association between HLA genotypes and COVID-19 susceptibility, severity and progression: A comprehensive review of the literature. Eur. J. Med. Res. 2021, 26, 84. [CrossRef]

8. Zakharova, M.Y.; Belyanina, T.A.; Sokolov, A.V.; Kiselev, I.S.; Mamedov, A.E. The Contribution of Major Histocompatibility Complex Class II Genes to an Association with Autoimmune Diseases. Acta Nat. 2019, 11, 4–12. [CrossRef]

9. Soto, M.E.; Vargas-Alarcón, G.; Cicero-Sabido, R.; Ramirez, E.; Alvarez-León, E.; Reyes, P.A. Comparison distribution of HLA-B alleles in Mexican patients with takayasu arteritis and tuberculosis. Hum. Immunol. 2007, 68, 449–453. [CrossRef]

10. Wieczorek, M.; Abualrous, E.T.; Sticht, J.; Álvarez-Benito, M.; Stolzenberg, S.; Noé, F.; Freund, C. Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation. Front. Immunol. 2017, 8, 292. [CrossRef]

11. Zavala-Ruiz, Z.; Strug, I.; Anderson, M.W.; Gorski, J.; Stern, L.J. A polymorphic pocket at the P10 position contributes to peptide binding specificity in class II MHC proteins. Chem. Biol. 2004, 11, 1395–1402. [CrossRef]

12. Dutta, M.; Dutta, P.; Medhi, S.; Borkakoty, B.; Biswas, D. Polymorphism of HLA class I and class II alleles in influenza A(H1N1)pdm09 virus infected population of Assam, Northeast India. J. Med. Virol. 2018, 90, 854–860. [CrossRef] [PubMed]

13. Albayrak, A.; Ertek, M.; Tasyaran, M.A.; Pirim, I. Role of HLA allele polymorphism in chronic hepatitis B virus infection and HBV vaccine sensitivity in patients from eastern Turkey. Biochem. Genet. 2011, 49, 258–269. [CrossRef] [PubMed]

14. Mosaad, Y.M.; Farag, R.E.; Arafa, M.M.; Eletreby, S.; El-Alfy, H.A.; Eldeek, B.S.; Tawhid, Z.M. Association of human leukocyte antigen Class I (HLA-A and HLA-B) with chronic hepatitis C virus infection in Egyptian patients. Scand. J. Immunol. 2010, 72, 548–553. [CrossRef] [PubMed]

15. Stephens, H.A.F. HLA and other gene associations with dengue disease severity. Curr. Top. Microbiol. Immunol. 2010, 338, 99–114.

16. Hendel, H.; Caillat-Zucman, S.; Lebuanec, H.; Carrington, M.; O’Brien, S.; Andrieu, J.M.; Schächter, F.; Zagury, D.; Rappaport, J.; Winkler, C.; et al. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J. Immunol. 1999, 162, 6942–6946.

17. Abraham, P.; Aggarwa, N.; Babu, G.R.; Barani, S.; Bhargava, B.; Bhatnagar, T.; Dhaman, A.S.; Gangakhedkar, R.R.; Giri, S.; ICMR COVID Study Group; et al. Laboratory surveillance for SARS-CoV-2 in India: Performance of testing & descriptive epidemiology of detected COVID-19, January 22–April 30, 2020. Indian J. Med. Res. 2020, 151, 424–437.

18. Available online: https://www.mohfw.gov.in/pdf/UpdatedDetailedClinicalManagementProtocolforCOVID19adultsdated24052021.pdf (accessed on 12 August 2022).
19. Prasad, N.; Yadav, B.; Singh, M.; Gautam, S.; Bhadauria, D.; Patel, M.; Kushwaha, R.; Yadav, D.; Singh, A.; Yachha, M.; et al. Humoral Immune Response of SARS-CoV-2 Infection and Anti-SARS-CoV-2 Vaccination in Renal Transplant Recipients. **Vaccines** 2022, 10, 385. [CrossRef]

20. Abbott Laboratories. SARS-CoV-2 IgG [Package Insert]. 2020. Available online: https://www.fda.gov/media/137383/download (accessed on 12 August 2022).

21. Knezevic, I.; Mattiuzzo, G.; Page, M.; Minor, P.; Griffiths, E.; Nuebling, M.; Moorthy, V. WHO International Standard for the evaluation of the antibody response to COVID-19 vaccines: Call for urgent action by the scientific community. *Lancet Microbe* 2022, 3, e235–e240. [CrossRef]

22. Cafiero, C.; Rosapepe, F.; Palmirotta, R.; Re, A.; Ottaiano, M.P.; Benincasa, G.; Perone, R.; Varriale, E.; D’Amato, G.; Cacciannia, A.; et al. Angiotensin System Polymorphisms in SARS-CoV-2 Positive Patients: Assessment Between Symptomatic and Asymptomatic Patients: A Pilot Study. *Pharmgenomics Pers. Med.* 2021, 14, 621–629. [CrossRef]

23. Lin, M.; Tseng, H.K.; Trejaut, J.A.; Lee, H.L.; Loo, J.H.; Chu, C.C.; Chen, P.; Su, Y.; Lim, K.H.; Tsai, Z.; et al. Association of HLA class I with severe acute respiratory syndrome coronavirus infection. *BMC Med. Genet.* 2003, 4, 9. [CrossRef]

24. Nguyen, A.; David, J.K.; Maden, S.K.; Wood, M.A.; Weeder, B.R.; Nellore, A.; Thompson, R.F. Human Leukocyte Antigen polymorphisms determine responses to bacterial superantigens. *J. Immunol.* 2004, 172, 1719–1726. [CrossRef]

25. Nikolich-Zugich, J.; Fremont, D.H.; Miley, M.J.; Messaoudi, I. The role of mhc polymorphism in anti-microbial resistance. *Microbes Infect.* 2004, 6, 501–512. [CrossRef] [PubMed]

26. Llewelyn, M.; Sriskandan, S.; Peakman, M.; Ambrozak, D.R.; Douek, D.C.; Kwok, W.W.; Cohen, J.; Altmann, D.M. HLA class II polymorphisms determine responses to bacterial superantigens. *J. Immunol.* 2004, 172, 1719–1726. [CrossRef] [PubMed]

27. COVID-19 Host Genetics Initiative. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2. *J. Virol.* 2020, 94, e00510-20. [CrossRef] [PubMed]

28. Romero-López, J.P.; Carnalla-Cortés, M.; Pacheco-Olvera, D.L.; Ocampo-Godínez, J.M.; Oliva-Ramírez, J.; Moreno-Manjón, J.; Bernal-Alfírez, B.; López-Olmendo, N.; García-Latorre, E.; Domínguez-López, M.L.; et al. A bioinformatic prediction of antigen presentation from SARS-CoV-2 spike protein revealed a theoretical correlation of HLA-DRB1*01 with COVID-19 fatality in Mexican population: An ecological approach. *J. Med. Virol.* 2021, 93, 2029–2038. [CrossRef]

29. Novelli, A.; Andreani, M.; Biancolella, M.; Liberatoscioli, L.; Passarelli, C.; Colona, V.L.; Rogliani, P.; Leonardis, F.; Campana, A.; Carsetti, R.; et al. HLA allele frequencies and susceptibility to COVID-19 in a group of 99 Italian patients. *HLA 2020*, 96, 610–614. [CrossRef]

30. Naemi, F.M.A.; Al-Adwani, S.; Al-Khatabi, H.; Al-Nazawi, A. Frequency of HLA alleles among COVID-19 infected patients: Preliminary data from Saudi Arabia. *Virology 2021*, 560, 1–7. [CrossRef]

31. Benotmane, I.; Gautier, G.; Perrin, P.; Olagne, J.; Cognard, N.; Fafi-Kremer, S.; Caillard, S. Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients with Minimal Serologic Response to 2 Doses. *JAMA 2021*, 326, 1063–1065. [CrossRef]

32. Kamar, N.; Abravanel, F.; Marion, O.; Couat, C.; Izopet, J.; del Bello, A. Three Doses of an mRNA COVID-19 Vaccine in Solid-Organ Transplant Recipients. *N. Engl. J. Med.* 2021, 385, 661–662. [CrossRef]

33. Prasad, N.; Bansal, S.B.; Yadav, B.; Manhas, N.; Yadav, D.; Gautam, S.; Kushwaha, R.; Singh, A.; Bhadauria, D.; Yachha, M.; et al. Seroconversion Rate After SARS-CoV-2 Infection and Two Doses of Either ChAdOx1-nCOV COVISHIELDTM or BBV-152 COVAXIN™ Vaccination in Renal Allograft Recipients: An Experience of Two Public and Private Tertiary Care Center. *Front. Immunol.* 2022, 13, 911738. [CrossRef]

34. Bhadauria, D.S.; Katiyar, H.; Goel, A.; Tiwari, P.; Kishore, R.V.K.; Aggarwal, A.; Verma, A.; Khetan, D.; Kaul, A.; Yachha, M.; et al. Antibody Response to ChAdOx1 nCoV-19 (AZD1222) Vaccine in Kidney Transplant Recipients. *Vaccines 2022*, 10, 1693. [CrossRef] [PubMed]

35. Cheng, G.S.; Evans, S.E. The paradox of immunosuppressants and COVID-19. *Eur. Respir. J.* 2022, 59, 2102828. [CrossRef] [PubMed]

36. Zhang, W.; Zhao, Y.; Zhang, F.; Wang, Q.; Li, T.; Liu, Z.; Wang, J.; Qin, Y.; Zhang, X.; Yan, X.; et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. *Clin. Immunol.* 2020, 214, 108393. [CrossRef] [PubMed]

37. Xu, Z.; Shi, L.; Wang, Y.; Zhang, J.; Huang, L.; Zhang, C.; Liu, S.; Zhao, P.; Liu, H.; Zhu, L.; et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir. Med.* 2020, 8, 420–422. [CrossRef]

38. Tang, Y.; Liu, J.; Zhang, D.; Xu, Z.; Ji, J.; Wen, C. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. *Front. Immunol.* 2020, 11, 1708. [CrossRef]

39. Yadav, B.; Prasad, N.; Agarwal, V.; Agarwal, V.; Jain, M. Hidden Granulocyte B-Mediated Injury in Chronic Active Antibody-Mediated Rejection. *Exp. Clin. Transpl.* 2020, 18, 778–784. [CrossRef]

40. Yadav, B.; Prasad, N.; Agarwal, V.; Jain, M.; Agarwal, V.; Jaiswal, A.; Bhadauria, D.; Sharma, R.K.; Gupta, A. T-bet-positive mononuclear cell infiltration is associated with transplant glomerulopathy and interstitial fibrosis and tubular atrophy in renal allograft recipients. *Exp. Clin. Transpl.* 2015, 13, 145–151. [CrossRef]

41. Yadav, B.; Prasad, N.; Agarwal, V.; Jain, M.; Agarwal, V. Role of pathogenic T-helper cells-17 in chronic antibody-mediated rejection in renal allograft recipients. *Indian J. Transpl.* 2022, 16, 88–95.